Core Insights - Insilico Medicine announced a research collaboration with Servier worth a total of $888 million, combining Insilico's AI-driven drug development platform with Servier's global expertise in oncology drug development [1] Group 1: Collaboration Details - The agreement allows Insilico to receive up to $32 million in upfront and near-term milestone payments [1] - Insilico will utilize its proprietary AI technology platform to identify and advance potential drug candidates that meet established drug development and scientific standards [1] - Servier will co-fund the research costs and will lead subsequent clinical validation, regulatory communication, and commercialization of promising oncology drug candidates globally after nomination [1]
英矽智能：与施维雅达成价值 8.88 亿美元的抗肿瘤药物研发合作